sugemalimab
cstone pharmaceuticals,eqrx
['lung', '9027', 'eqrx']
new overall survival data of our investigational anti-pd-l1 therapy for stage iv non-small cell lung cancer at asco22 (abstract #9027). watch why we aim to couple scientific innovation with pricing innovation to increase patient access globally.
EQRx is a new type of pharmaceutical company committed to developing & delivering innovative medicines to patients at RADICALLY lower prices. #RemakingMedicine